



JC14 Rec'd PCT/PTO 05 JUL 2001

PATENT
ST98009A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): BYK ET AL. EXAMINER: W. ALVARADO
SERIAL NO. : 09/647,678 ART UNIT :
FILED : OCTOBER 2, 2000
FOR : NEW AGENTS FOR TRANSFERRING NUCLEIC ACIDS,
COMPOSITIONS CONTAINING THEM AND THEIR USES

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on July 3, 2001.

William C. Coppola, Reg. No. 41,686
(Name of Registered Representative)

Genelia Walker
(Signature and Date)

INFORMATION DISCLOSURE STATEMENT UNDER
37 C.F.R. 1.56, 1.97 AND 1.98

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Dear Sir:


Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication, or other information referred

to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b)(3), because it is being filed before the mailing of a first office action on the merits. However, if it is subsequently determined that this information disclosure statement has been filed after the mailing of a first office action, the Commissioner is hereby authorized to charge any fee due under 37 C.F.R. 1.17(P), or credit any overpayment, to account No. 18-1982.

Applicants concurrently submit herewith a PTO-1449 form and copies of references listed therein.

Respectfully submitted,



William C. Coppola
Attorney for Applicants
Registration No. 41,686

Aventis Pharmaceuticals Products Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4854

Please type a plus sign (+) inside this box


 1449A/PTO JUL 05 2001 U.S. Department of Commerce
 Patent and Trademark Office

**LIST OF PRIOR ART CITED BY
 APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/647,678
Filing Date	OCTOBER 2, 2000
First Named Inventor	BVK ET AL.
Group Art Unit	
Examiner Name	W. ALVARADO
Attorney Docket Number	ST98009A

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office 3	Number4	Kind Code (if known)				
	A	EP	0394111	-		10-24-1990		
	B	WO	93/05162	-		03-18-1993		
	C	WO	95/18863	-		06-13-1995		
	D	WO	96/17823	-		06-13-1996		
	E	WO	97/31935	-		04-09-1997		
	F	WO	97/18185	-		05-22-1997		

EXAMINER SIGNATURE

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached kinds of U.S. Patent Documents. Enter Office that issued the document, by the two letter code (WIPO Standard ST.3). For ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents,